Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of MN-166 ER vs IR in Healthy Volunteers
NCT03533387Phase 1Completed
- Sponsor
- MediciNova, Inc.
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibudilast in amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and substance use disorder (SUD) (3 arms), sponsored by MediciNova, Inc. Primary endpoint: Pharmacokinetic Profile of two new formulations in Single-day dose of MN-166 at 5 weeks. Started Apr 2018; status: completed.
02
Drugs
ibudilast
03
Conditions
amyotrophic lateral sclerosis (ALS)multiple sclerosis (MS)substance use disorder (SUD)
Beyond the preview
Go deeper on NCT03533387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533387.